Gain Therapeutics GANX 深 沪
等待开盘 09-17 09:30:00 美东时间
1.63
-0.010
-0.61%
华盛通- 最 高1.6999
- 今 开1.68
- 成交量 54.80万股
- 最 低 1.595
- 昨 收 1.64
- 总市值 4881.13万
- 52周最高 3.19
- 市盈率 静 --
- 换手率 1.83%
- 52周最低 1.41
- 委 比 85.74%
- 总股本 2994.56万
- 历史最高 17.93
- 量 比 1.12
- 振 幅 6.40%
- 历史最低 0.89
- 每 手 1
- 风险率 0.32%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation
Gain Therapeutics announced that its Phase 1b clinical trial for GT-02287, a potential treatment for Parkinson's disease, has been extended by nine months for participants who completed the initial three-month study. The independent data monitoring committee (DMC) reviewed interim safety data and recommended continuing the study without changes. GT-02287, an orally administered, brain-penetrant small molecule, aims to restore lysosomal enzyme fun...
09-04 12:00
美股大行评级 | 潜在涨幅95.33%！HC Wainwright & Co.上调Insmed目标价至240美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Insmed"买入"评级，目标价从120美元升至240美元；巴克莱：维持Transocean"超配"评级，目标价从3.5美元升至4美元
08-14 09:25
Roth Capital Maintains Buy on Gain Therapeutics, Lowers Price Target to $6
Roth Capital analyst Boobalan Pachaiyappan maintains Gain Therapeutics (NASDAQ:GANX) with a Buy and lowers the price target from $7 to $6.
08-14 01:14
Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference
Gain Therapeutics announced that its management team will participate in a fireside chat and one-on-one meetings at BTIG's Annual Virtual Biotechnology Conference from July 29 to 30, 2025. The fireside chat is scheduled for July 30 at 3:20pm ET. Gain is a clinical-stage biotech company focused on next-generation allosteric therapies, with its lead candidate, GT-02287, in a Phase 1b trial for Parkinson's disease. The company's Magellan platform ac...
07-24 12:53
US Futures Trade Mixed As June Inflation Ticks Up: ASML, Morgan Stanley, Goldman Sachs, BofA Earnings In Focus
U.S. stock futures swung between gains and losses on Wednesday after ending on a mixed note on Tuesday. Futures of major benchmark indices were mixed.
07-16 18:08
Why Data Storage Shares Are Trading Higher By 35%; Here Are 20 Stocks Moving Premarket
Shares of Data Storage Corporation (NASDAQ:DTST) rose sharply in pre-market tra...
07-16 18:04
Gain Therapeutics Announces Pricing of $7.0 Million Public Offering
Gain Therapeutics announced the pricing of a public offering of 4.5 million shares of common stock and warrants to purchase 2.25 million shares, priced at $3.11 per set of securities. The company expects to raise approximately $7 million, excluding underwriting discounts. The offering is set to close on July 17 and the proceeds will be used for clinical development of its lead candidate GT-02287 for neurodegenerative diseases like GBA1 Parkinson’...
07-16 13:03
Gain Therapeutics announces proposed public offering
Gain Therapeutics (NASDAQ:GANX) announced on Tuesday that it is proposing to offer and sell shares of its common stock and warrants to purchase common stock in an underwritten public offering. The com...
07-16 04:41
Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson’s Disease With or Without a GBA1 Mutation
Gain Therapeutics reported that its Phase 1b clinical trial for GT-02287 in Parkinson’s Disease patients reached the enrollment goal of 16 participants ahead of schedule by June 30, 2025. Biomarker analysis from cerebrospinal fluid samples, initially expected in 1Q 2026, will now be available earlier in 4Q 2025. The company extended the patient screening window to July 31, 2025, and plans to request a dosing extension beyond the 90-day protocol. ...
06-30 20:05
Gain Therapeutics Doubles Authorized Common Stock Shares
Gain Therapeutics ( ($GANX) ) has shared an update. On June 24, 2025, Gain Ther...
06-25 05:29
